Finding the Best Stocks Under $30: Two Promising Companies Worth Your Consideration

The notion that you need a substantial amount to begin investing in stocks is outdated. Modern online brokers have democratized market access through low-cost or commission-free trading and fractional share purchases, allowing entry at virtually any investment level. Yet for those seeking to own at least one complete share, an exciting opportunity exists: numerous quality companies trade at prices well below the $30 mark. Two particularly compelling examples deserve investor attention: Exelixis (NASDAQ: EXEL) and Adyen (OTC: ADYE.Y). Understanding why these best stocks under $30 matter requires examining their business fundamentals and growth trajectories.

Exelixis: A Biotech Powerhouse Driving Cancer Treatment Innovation at an Accessible Price

Exelixis operates within the biotech sector, concentrating its efforts on cancer drug development. The company’s financial performance has historically centered around a single pharmaceutical blockbuster: Cabometyx, its flagship treatment for specific liver and kidney cancer variants. This drug has functioned as a continuous innovation engine, consistently expanding its approved indications while generating expanding revenue streams.

Financial momentum tells a compelling story. The company’s annual revenue climbed 13.6% year-over-year, reaching $1.8 billion in the period measured, while earnings per share grew approximately 16% compared to the preceding fiscal year. These metrics underscore the business’s underlying strength, particularly when considering the company’s strategic pathway forward.

The development strategy remains focused on expanding Cabometyx’s market reach. Exelixis is pursuing additional regulatory approvals, notably for treating metastatic castration-resistant prostate cancer—a devastating diagnosis often associated with survival periods measured in just two years. Such conditions represent precisely the therapeutic gaps where the company has demonstrated historical expertise and success potential.

However, management recognizes the risks inherent in product concentration. Diversification efforts center on zanzalintinib, currently progressing through multiple Phase 3 clinical studies. One target indication is metastatic colorectal cancer, where opportunity remains substantial. Early-stage detection offers patients approximately 91% five-year survival odds, yet once disease spreads to distant organs like the liver and lungs, that figure plummets to just 13%. This disparity underscores the genuine market need for improved therapeutic options.

Beyond these primary candidates, the company maintains an active pipeline of early-stage trials and strategic partnerships with other biotech firms aimed at future asset discovery. The organization has demonstrated consistent ability to advance research and achieve regulatory milestones. The current stock under $30—trading just below $21 per share—positions the company as an attractive entry point for long-term investors believing in continued innovation and clinical progress.

Adyen: A Fintech Player Positioned for Resilience Despite Recent Challenges

Adyen, the Netherlands-based fintech company, encountered a difficult operating period characterized by slowed revenue expansion and margin compression. Multiple factors contributed to this performance. First, the company’s strategic choice to increase future investment—while competitors were implementing workforce reductions—created near-term financial headwinds. Second, competitive pressure intensified as players like PayPal expanded offerings in Adyen’s core payment processing niche.

The company operates a comprehensive platform enabling merchants to accept payments across multiple global regions, functioning simultaneously as an acquiring processor and point-of-sale service provider with integrated risk management capabilities. This breadth creates competitive challenges, particularly in the lucrative U.S. market where entrenched competitors are strengthening positions.

Yet fundamentals warrant optimistic consideration. The company processed 970.1 billion euros (approximately $1.1 trillion) in transaction volume—a 26% annual increase. Revenue grew 22% year-over-year to 1.6 billion euros ($1.7 billion), demonstrating that despite competitive pressures, the business maintains meaningful expansion. While EBITDA margins compressed to 46% from the prior year’s 55%, management has since decelerated aggressive hiring, signaling confidence that margin recovery will follow.

A critical competitive advantage deserves emphasis: switching costs. Merchants cannot easily transition payment providers without substantial operational planning, integration complexity, and risks of accepting payment methods their customer base doesn’t prefer. This friction creates a durable business moat—a genuine competitive barrier protecting the customer base. Such structural advantages matter significantly for long-term value creation in the rapidly expanding fintech ecosystem.

The current valuation stands just under $16 per share. Combined with the company’s market position within a growing industry, these factors suggest stocks under $30 like Adyen merit consideration from patient, long-term oriented investors.

The Investment Case: Why These Best Stocks Under $30 Matter

Both Exelixis and Adyen represent different risk-reward profiles within the sub-$30 price range. Exelixis offers exposure to biotech innovation with concentrated but proven revenue drivers and promising pipeline expansion. Adyen provides fintech exposure with established market position, operational moat, and recovery potential following a challenging operating period.

The accessibility of these price points democratizes quality company ownership. Rather than requiring substantial capital to acquire meaningful positions, investors can build diversified holdings featuring companies with genuine competitive advantages and growth narratives. When evaluating stocks under $30 in your portfolio construction, fundamental analysis should focus on sustainable competitive advantages, management execution track records, and whether current valuations offer attractive entry points for multi-year holding periods.

The investment thesis supporting these companies rests not on stock price alone, but on underlying business strength, addressable market opportunity, and management’s demonstrated ability to navigate their respective industries. That combination creates the foundation for what may constitute your best stocks under $30 for long-term wealth building.